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Introduction
Heart failure places a major burden on the healthcare 
system in the western world (Bleumink et al 2004). The 
prevalence of heart failure is predicted to increase in 
the coming decades (Stewart et al 2003). However, the 
healthcare burden of heart failure does not pertain solely 
to the constantly increasing number of patients. Recurrent 
exacerbation periods impair the physical and psychological 
condition of the patient, require frequent re-hospitalisation, 
and are associated with poorer prognosis (Stewart et al 
2003, Bleumink et al 2004). The risks of mortality and re-
hospitalisation are difﬁcult to predict with precision in the 
population of people with heart failure. Most tests aimed 
at determining factors that could be used as predictors 
of morbidity and mortality in this group of patients are 
complicated and expensive, which prevent them from being 
cost effective.
A marked reduction in the capacity to undertake physical 
activity is one of the principal symptoms of heart failure. 
Therefore, potential associations have been investigated 
between various methods of assessing physical exercise 
capacity and prognosis (Sarullo et al 2010, Poggio et al 2010). 
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Question: Does the distance covered during a 6-minute walk test predict risk of death or hospitalisation for cardiovascular 
reasons in men with stable heart failure over three years of follow-up? Design: Prospective observational study. 
Participants: 243 men with stable systolic heart failure, with a mean age of 60 yr (SD 11) and left ventricular ejection 
fraction of 29% (SD 8). According to the New York Heart Association (NYHA) classiﬁcation, 15% of the participants were in 
Class I, 44% in Class II, 37% in Class III, and 4% in class IV. Outcome measures: The exercise capacity of participants was 
measured using the 6-minute walk test. The participants were followed up for at least three years in the case of survivors. 
The primary end-points of the survival analyses included cardiovascular death or urgent cardiovascular hospitalisation. 
Results: During the 3-year follow-up, 44% of the participants died, and 69% died or required hospitalisation for 
cardiovascular reasons. A multivariate analysis showed that the shorter the distance covered in the 6-minute walk test, 
the greater the 1-year and 3-year mortality risk. Participants with a 6-minute walk test ) 468 m had a mortality hazard ratio 
of 3.22 (95% CI 1.17 to 8.86) at one year and 2.18 (95% CI 1.18 to 4.03) at three years. Multivariate analysis also showed 
that higher risk mortality or hospitalisation for cardiovascular reasons was predicted by a 6-minute walk distance ) 468 
m, with a hazard ratio of 2.77 (95% CI 1.30 to 5.88) at one year and 1.71 (95% CI 1.08 to 2.72) at three years. Conclusion: 
The 6-minute walk test distance constitutes an independent predictor of mortality and mortality or hospitalisation for 
cardiovascular reasons in men with stable systolic heart failure. [Wegrzynowska-Teodorczyk K, Rudzinska E, Lazorczyk 
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Many predictor variables from formal cardiopulmonary 
exercise testing have been proposed, including peak oxygen 
consumption as a percentage of the predicted value, the 
chronotropic index, and ventilatory efﬁciency (Poggio et al 
2010). When multiple predictors are available, conﬂicting 
predictions can make interpretation difﬁcult (Poggi et al 
2010).
The 6-minute walk test is a simple and inexpensive method 
of indirectly assessing physical capacity that is widely 
available and commonly used (Bellet et al 2011, Rostagno 
et al 2008, Faggiano et al 2004). Most previous studies have 
8IBUJTBMSFBEZLOPXOPOUIJTUPQJDThe 6-minute 
walk test is a simple and inexpensive method of 
indirectly assessing exercise tolerance. The distance 
covered by hospitalised patients during the test is 
predictive of the 1-year risk of cardiovascular death.
8IBUUIJTTUVEZBEET Among men with chronic heart 
failure, the 1- and 3-year mortality risk are greater 
among those who cover less than 468 m on the 
6-minute walk test.
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demonstrated that the distance covered by hospitalised 
patients during a 6-minute walk test is predictive of the 
one-year risk of cardiovascular death (Cahalin et al 1996, 
Opasich et al 2001, Shah et al 2001). However, few studies 
have examined the predictive ability of the 6-minute walk 
test distance beyond one year.
The speciﬁc research questions for this study were:
1. Are there relationships between the distance covered 
during the 6-minute walk test and the clinical 
characteristics of men with stable heart failure?
2. What are the 1-year and 3-year mortality and 
hospitalisation rates among men with stable heart 
failure?
3. Is the distance covered in the 6-minute walk test 
associated with mortality and hospitalisation for 
cardiovascular reasons at one and three years?
Method
Design
This was a prospective, longitudinal, observational study 
in which the predictive ability of the 6-minute walk test 
distance was assessed in men with stable heart failure. 
Participants were followed up for a minimum of three 
years. The clinical outcomes assessed were mortality and 
hospitalisation for cardiovascular reasons.
Participants
Participants were recruited from the Heart Failure 
Outpatient Clinic of the Center for Heart Disease in 
Wroclaw, Poland. Male clinic attendees with stable systolic 
heart failure were approached consecutively and informed 
about what participation in the study would entail. Those 
who expressed interest in participation underwent a cardiac 
evaluation and this was used to assess whether they met the 
eligibility criteria.
The inclusion criteria were: male aged over 18 years, a 
documented history of heart failure of six months or longer, 
a left ventricular ejection fraction (LVEF) of 45% or lower 
as assessed by echocardiography (performed at the time 
of screening using a Simpson’s planimetric method), and 
clinical stability indicated by unchanged medications for at 
least one month prior to enrolment. The exclusion criteria 
were: acute coronary syndrome, coronary revascularisation 
and/or major surgery within the three months prior to 
enrolment, unplanned hospitalisation due to heart failure 
deterioration or any other cardiovascular reason within 
one month prior to enrolment, any condition precluding the 
independent performance of a walk test, and unwillingness 
or inability to provide written informed consent.
Outcome measures
Laboratory tests. Venous blood samples were taken in the 
morning following an overnight fast and after resting for at 
least 15 min. Standard laboratory tests, including complete 
blood count, serum levels of haemoglobin, creatinine, and 
uric acid, were performed using the standardised laboratory 
methods in our institution. Plasma levels of N-terminal 
pro-brain natriuretic peptide (NT-proBNP) were measured 
in pg/mL using the enzyme-linked immunosorbent assay 
methoda, and C-reactive protein (hsCRP) serum levels were 
determined by an immunonephelometric high sensitivity 
methodb. Renal function was assessed via the estimated 
glomerular ﬁltration rate (eGFR) using the Modiﬁcation in 
Diet in Renal Disease calculator, ie, 186 × (serum creatinine 
levels)–1.154 × (age)–0.203.
6-minute walk test. The 6-minute walk test was performed 
in a long, straight hospital corridor, over a 30-m distance. 
Each participant was asked to walk (not run) back and 
forth along the corridor as briskly as possible, so that the 
longest possible distance was covered in six minutes. The 
participant was allowed to slow down or stop and rest if 
necessary, particularly in the case of symptoms such as 
severe dyspnoea or fatigue. During any rest period, the 
participant was informed of the elapsed time and encouraged 
to recommence walking when the symptoms attenuated 
enough to allow walking. However, the test was discontinued 
if the symptoms persisted. The participant was also allowed 
to discontinue the test at will at any time. Moreover, the 
test was interrupted by the investigator immediately one 
of the following symptoms appeared: chest pain that did 
not resolve at rest, dyspnoea precluding continuation 
of walking, cramps of the lower limb muscles, balance 
difﬁculty, severe sweating, pallor, or cyanosis. Otherwise, 
every two minutes during the test, an investigator informed 
the participant of the amount of time left and encouraged 
him to continue the test. At six minutes, the participant was 
advised to stop and be seated. An investigator immediately 
measured post-exercise arterial blood pressure and pulse 
rate. The participant assessed subjective fatigue and 
dyspnoea levels with the modiﬁed Borg scale from 0 (none) 
to 10 (maximal). The distance walked was measured to the 
nearest whole metre.
Long-term clinical outcomes. Information regarding 
survival and hospitalisation was obtained directly from 
the participant, over the phone from the participant or 
their relatives, from the hospital system, or from the heart 
failure clinic database. The participants who survived were 
followed up for at least three years. The ﬁrst end-point of 
this study was cardiovascular death. The second end-point 
of this study was a composite outcome: death or urgent 
hospitalisation for cardiovascular reasons.
Data analysis
Continuous variables with a normal distribution (ie, age, 
6-minute walk test distance, LVEF, eGFR, haemoglobin, 
and uric acid) were presented as means and standard 
deviations. The between-group differences were tested 
using Student’s t-test. The remaining continuous variables 
(ie, plasma NT-proBNP and serum hs-CRP) had a skewed 
distribution and were expressed as medians with lower 
and upper quartiles. These between-group differences 
were tested using the Mann Whitney U-test. For further 
analyses, these variables were log transformed in order to 
normalise their distribution. The categorical variables were 
expressed as numbers with percentages. The between-group 
differences were tested using the chi-squared test.
The relationship between the 6-minute walk test and 
the long-term clinical outcomes was assessed by using 
univariate and multivariate regression models. The 
associations between the analysed parameters and survival 
were established using Cox proportional hazards analysis. 
The number of variables included in the multivariable 
models was dependent on the number of events (ie, 1 
predictor for 10 events). The following parameters were 
included in the analyses as potential predictors of death, 
and death or hospitalisation: age, heart failure aetiology, 
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Table 1. Mean (SD) of groups, mean (SD) difference within groups, and mean (95% CI) difference between groups.
Characteristic Participants
All 1-year follow-up 3-year follow-up
(n = 243) Survived 
 (n = 204)
Died 
 (n = 39)
p Survived 
 (n = 136)
Died 
 (n = 107)
p
Age (yr), mean (SD) 60 (11) 60 (11) 60 (10) 60 (10) 60 (10)
BMI (kg/m2), mean (SD) 27.7 (4.6) 27.7 (4.8) 27.1 (4.1) 28.1 (4.7) 27.0 (4.5) < 0.05
Ischaemic aetiology, n (%) 163 (67) 129 (63) 34 (87) < 0.05 93 (68) 70 (65)
NYHA class, n (%) < 0.001 < 0.001
 I 35 (15) 33 (16) 2 (5) 26 (19) 11 (10)
 II 107 (44) 98 (48) 10 (26) 73 (54) 34 (32)
 III 90 (37) 70 (34) 20 (51) 38 (28) 52 (49)
 IV 10 (4) 3 (1) 7 (18) 0 (0) 10 (9)
LVEF (%), mean (SD) 29 (8) 30 (9) 26 (9) < 0.01 31 (9) 27 (8) < 0.05
Diabetes mellitus, n (%) 70 (29) 59 (29) 11 (28) 40 (29) 30 (28)
Hypertension, n (%) 112 (46) 95 (47) 17 (44) 75 (55) 37 (35) < 0.05
NT-proBNP (pg/mL), median (IQR) 1438 
(408 to 4279)
1251 
(384 to 3487)
6987 
(1197 to 8206)
< 0.01 708 
(341 to 2515)
3119 
(896 to 7322)
< 0.01
hsCRP (mg/L), median (IQR) 3.3 
(1.4 to 6.8)
2.1 
(1.4 to 12.1)
7.5 
(2.0 to 12.1)
< 0.05 2.1 
(1.4 to 5.8)
4.2 
(1.5 to 7.4)
< 0.05
Haemoglobin (g/dL), mean (SD) 14.1 (1.5) 14.2 (1.5) 13.5 (1.8) < 0.05 14.4 (1.4) 13.7 (1.7) < 0.05
eGFR (mL/min/1.73m2), mean (SD) 72.3 (19.2) 73.8 (19.8) 66.5 (17.6) < 0.05 75.6 (20.6) 68.3 (17.4) < 0.05
Uric acid (g/dL), mean (SD) 6.9 (2.1) 6.5 (1.9) 8.4 (2.1) < 0.05 6.5 (1.8) 7.5 (2.3) < 0.05
Medications, n (%)
 "$&*BOEPS"3# 228 (94) 191 (93) 37 (95) 129 (95) 99 (92)
 Beta-blocker 213 (88) 178 (87) 35 (90) 120 (88) 93 (87)
 Digoxin 80 (33) 64 (31) 16 (41) < 0.05 40 (29) 40 (37) < 0.05
 Statin 167 (69) 139 (68) 28 (72) 94 (69) 73 (68)
 Loop diuretic 201 (83) 167 (82) 34 (87) 105 (77) 96 (90) < 0.01
BMI = body mass index, NYHA = New York Heart Association, LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal pro-I type natriuretic peptide, hsCRP = high-sensitivity C-reactive 
protein, eGFR = estimated glomerular ﬁltration rate, ACE-I = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker.
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NYHA class, LVEF%, NT-proBNP (log), haemoglobin, hs-
CRP (log), uric acid, renal function assessed using eGFR, 
the presence of diabetes mellitus, hypertension, and the 
6-minute walk test distance. The 6-minute walk test was 
included in Cox regression analysis as a continuous variable 
and as a dichotomous variable determined by the median.
In order to illustrate the relationship between 6-minute walk 
test distance and 3-year event-free survival rates, Kaplan-
Meier curves for cumulative survival were constructed. The 
median distance of the walk was considered an arbitrary 
cut-off point during the curve construction. Differences in 
event-free survival rates were tested using the Cox-Mantel 
log-rank test. A value of p < 0.05 was considered statistically 
signiﬁcant.
Results
Compliance with the study method
Among the 243 men recruited for the study, all who survived 
were followed up for at least three years. No surviving 
participant was lost to follow-up.
Characteristics of participants
The clinical characteristics of the study participants are 
presented in Table 1. The mean distance covered during 
the baseline 6-minute walk test was 444 m (SD 129). The 
participants’ mean scores on the 0–10 Borg scale were 6 
(SD 1) for dyspnoea and 5 (SD 2) for fatigue. The mean 
distance covered during the 6-minute walk test decreased 
progressively through the NYHA class subgroups: 566 m 
(SD 80) in Class I, 492 m (SD 95) in Class II, 356 m (SD 97) 
in Class III, and 227 m (SD 55) in Class IV.
Research question 1
Table 2 summarises the relationships between the distance 
covered during the 6-minute walk test and various clinical 
characteristics of the participants. In the multivariate 
analysis, shorter distances on the 6-minute walk test were 
found in participants with advanced age, heart failure of 
ischaemic aetiology, and advanced heart failure (advanced 
NYHA class, lower LVEF, lower eGFR and higher uric 
acid).
Research question 2
The mean follow-up period for all participants was 931 
days (SD 474, median 990, range 6 to 1774). The 1-year 
and 3-year mortality rates were 16% and 44%, respectively. 
The participants who died had higher NYHA classiﬁcations 
and lower LVEF, eGFR, BMI, and haemoglobin. The 
participants who died also had higher levels of NT-proBNP, 
hsCRP and UA, as presented in Table 1. During the 1-year 
and 3-year follow-up, 54% and 69% participants were 
urgently admitted to hospital for cardiovascular reasons or 
died.
3FTFBSDIRVFTUJPO
The proportionality assumption and the assumption of a 
log-linear relationship between the potential predictors and 
the hazard function were fulﬁlled for all tested variables. 
The 1-year prediction models are presented in Tables 3 and 
4. The 3-year prediction models are presented in Tables 5 
and 6.
The following variables showed a signiﬁcant association 
with a higher 1-year risk of cardiovascular death, and 
of death or hospitalisation, in the single predictor (ie, 
univariate) Cox proportional hazards models: high 
NYHA class, low LVEF, high NT-proBNP, high hsCRP, 
low haemoglobin, low eGFR, high uric acid, and low 
6-minute walk test distance (all p < 0.05), as presented 
in Tables 3 and 4. Interestingly, exactly the same factors 
were related to an increase in the composite outcome of 
3-year cardiovascular death or hospitalisation in this group 
of participants with chronic heart failure, as presented in 
Table 6. On multivariate analysis, high plasma NT-proBNP 
and low 6-minute walk test distance were strong predictors 
of the 1-year risk of death, as presented in Table 3.
More events occurred for the composite outcome ‘death 
or hospitalisation’ than for death alone. Therefore, the 
multivariate models permitted the inclusion of more 
Table 2. Clinical determinants of distance 6-minute walk test (univariate and multivariable 
logistic regression models).
Determinants Univariate models Multivariate models
r p r p
Age, 10 years –0.34 < 0.001 –0.24 0.002
Ischaemic aetiology 0.23 0.002 0.12 0.05
NYHA class –0.67 < 0.001 –0.55 < 0.001
LVEF, % 0.21 0.004 0.16 0.009
Diabetes mellitus –0.26 < 0.001 –0.07 0.19
Hypertension 0.02 0.80 0.01 0.93
/5QSP#/1MPHQHN- –0.32 <0.001 –0.10 0.13
IT$31MPHNH- –0.23 0.02 –0.11 0.47
)BFNPHMPCJOHE- 0.34 < 0.001 0.05 0.42
F('3N-NJO2 0.27 < 0.001 –0.20 0.01
6SJDBDJENH- –0.16 0.03 –0.18 0.04
NYHA = New York Heart Association, LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal 
pro-I type natriuretic peptide, hsCRP = high-sensitivity C-reactive protein, eGFR = estimated 
glomerular ﬁltration rate
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5BCMF. Predictors of 1-year cardiovascular death in men with chronic heart failure with uni- and multivariate Cox proportional hazard models.
Predictor Univariate model Multivariate modela Multivariate modelb
Hazard 
ratio
95% CI r2 p Hazard 
ratio
95% CI r2 p Hazard 
ratio
95% CI r2 p
Age 
per 10 yr
1.01 0.97 to 1.03 0.01 0.96 0.98 0.95 to 1.01 1.28 0.26 0.98 0.95 to 1.01 1.82 0.18
Ischaemic aetiology 
yes vs no
1.08 0.55 to 2.0 0.03 0.86
NYHA class 
(I–II vs III–IV)
2.26 1.46 to 3.49 13.3 < 0.001 1.27 0.70 to 2.30 0.60 0.44 1.31 0.76 to 2.28 0.93 0.34
LVEF% 
per 1%
0.94 0.91 to 0.98 9.14 0.003
Diabetes mellitus 
yes vs no
0.70 0.33 to 1.46 0.92 0.34
Hypertension 
yes vs no
0.55 0.28 to 1.09 2.95 0.09
NT-proBNP 
QFSMPHQHN-
1.64 1.32 to 2.16 17.67 < 0.001 1.46 1.14 to 1.87 9.27 0.002 1.46 1.15 to 1.86 9.72 0.002
hsCRP 
QFSMPHNH-
1.91 1.27 to 2.85 9.84 0.002
Haemoglobin 
QFSHE-
0.77 0.65 to 0.92 8.36 0.004
eGFR 
QFSN-NJO2
0.91 0.83 to 0.98 5.27 0.02
Uric acid 
QFSNH-
1.37 1.25 to 1.61 28.32 < 0.001
6MWT distance 
per 10 m
0.95 0.92 to 0.97 17.71 < 0.001 0.96 0.93 to 0.99 4.01 0.04 – – – –
6MWT distance 
) 468 vs > 468 m
3.90 1.86 to 8.17 13.00 < 0.001 – – – – 3.22 1.17 to 8.86 5.14 0.02
r2 of the model 31.28 < 0.001 32.78 < 0.001
NYHA = New York Heart Association, LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal pro-I type natriuretic peptide, hsCRP = high-sensitivity C-reactive protein, eGFR = 
estimated glomerular ﬁltration rate. HR was analysed for increasing the level of a given variable by r number of units presented in the Table. a6MWT distance as a continuous variable. b6MWT 
distance as a dichotomous variable
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Table 4. Predictors of 1-year cardiovascular death or hospitalisation in men with chronic heart failure with uni- and multivariate Cox proportional hazard models.
Predictor Univariate model Multivariate modela Multivariate modelb
Hazard 
ratio
95% CI r2 p Hazard 
ratio
95% CI r2 p Hazard 
ratio
95% CI r2 p
Age 
per 10 yr
1.01 0.89 to 1.18 0.01 0.87 0.99 0.95 to 1.02 0.62 0.43 0.99 0.95 to 1.01 0.71 0.40
Ischaemic aetiology 
yes vs no
0.94 0.58 to 1.54 0.06 0.81
NYHA class 
(I–II vs III–IV)
2.83 1.72 to 4.65 22.56 < 0.001 0.92 0.54 to 1.58 0.08 0.77 1.05 0.65 to 1.71 0.05 0.83
LVEF% 
per 1%
0.97 0.94 to 1.00 6.02 0.02 1.01 0.97 to 1.05 0.22 0.64 1.00 0.97 to 1.05 0.16 0.69
Diabetes mellitus 
yes vs no
1.10 0.66 to 1.84 0.14 0.71 0.99 0.53 to 1.84 0.01 0.96 0.92 0.49 to 1.73 0.06 0.80
Hypertension 
yes vs no
1.28 0.78 to 2.09 0.82 0.33 2.22 0.71 to 6.67 1.83 0.18 2.01 0.68 to 6.25 1.64 0.20
NT-proBNP 
QFSMPHQHN-
1.57 1.27 to 1.89 21.24 < 0.001 1.27 0.98 to 1.64 3.39 0.07 1.28 1.00 to 1.64 3.78 0.05
hsCRP 
QFSMPHNH-
1.76 1.26 to 2.45 12.16 0.001 1.39 0.91 to 2.09 2.43 0.12 1.25 0.83 to 1.88 1.17 0.28
Haemoglobin 
QFSHE-
0.79 0.69 to 0.90 11.61 0.001 0.91 0.77 to 1.08 1.18 0.28 0.89 0.75 to 1.06 1.62 0.20
eGFR 
QFSN-NJO2
0.91 0.85 to 0.96 9.53 0.002 0.92 0.85 to 1.02 2.35 0.13 0.94 0.86 to 1.03 1.62 0.20
Uric acid 
QFSNH-
1.32 1.18 to 1.49 29.80 < 0.001 1.19 1.02 to 1.38 4.78 0.03 1.22 1.04 to 1.42 6.15 0.01
6MWT distance 
per 10 m
0.95 0.93 to 0.97 24.68 < 0.001 0.95 0.93 to 0.98 6.90 0.009 – – – –
6MWT distance 
) 468 vs > 468 m
3.39 1.98 to 5.81 19.77 <0.001 – – – – 2.77 1.30 to 5.88 7.00 0.008
r2 of the model 68.38 < 0.001 58.93 < 0.001
NYHA = New York Heart Association, LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal pro-I type natriuretic peptide, hsCRP = high-sensitivity C-reactive protein, eGFR = 
estimated glomerular ﬁltration rate. HR was analysed for increasing the level of a given variable by r number of units presented in the Table. a6MWT distance as a continuous variable. b6MWT 
distance as a dichotomous variable
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Table 5. Predictors of 3-year cardiovascular death in men with chronic heart failure with uni- and multivariate Cox proportional hazard models.
Predictor Univariate model Multivariate modela Multivariate modelb
Hazard 
ratio
95% CI r2 p Hazard 
ratio
95% CI r2 p Hazard 
ratio
95% CI r2 p
Age 
per 10 yr
1.13 0.88 to 1.46 0.10 0.76 0.99 0.97 to 1.03 0.01 0.95 01.00 0.97 to 1.02 0.09 0.76
Ischaemic aetiology 
yes vs no
2.14 0.68 to 6.73 0.12 0.19 0.89 0.47 to 1.67 0.13 0.72 0.81 0.43 to 1.55 0.40 0.53
NYHA class 
(I–II vs III–IV)
1.90 1.43 to 2.52 19.38 < 0.001 1.30 0.82 to 2.02 1.29 0.25 1.26 0.83 to 1.90 1.19 0.27
LVEF% 
per 1%
0.98 0.92 to 0.97 17.3 < 0.001 0.98 0.94 to 1.00 2.01 0.16 0.98 0.95 to 1.01 1.68 0.19
Diabetes mellitus 
yes vs no
1.46 0.58 to 3.65 0.07 0.42
Hypertension 
yes vs no
1.77 0.71 to 4.44 0.45 0.22
NT-proBNP 
QFSMPHQHN-
1.61 1.37 to 1.88 34.76 < 0.001 1.37 1.12 to 1.67 9.35 0.002 1.37 1.12 to 1.66 9.69 0.002
hsCRP 
QFSMPHNH-
1.02 0.96 to 1.09 0.31 0.52 1.09 0.80 to 1.47 0.29 0.59 1.04 0.77 to 1.41 0.07 0.79
Haemoglobin 
QFSHE-
0.82 0.72 to 0.92 10.69 0.001 1.02 0.87 to 1.18 0.04 0.83 1.02 0.88 to 1.19 0.07 0.80
eGFR 
QFSN-NJO2
0.96 0.73 to 1.25 0.12 0.73 1.00 0.94 to 1.08 0.02 0.89 1.00 0.93 to 1.08 0.01 0.96
Uric acid 
QFSNH-
1.31 1.05 to 1.64 5.12 0.02 1.13 1.00 to 1.28 3.95 0.05 1.15 1.02 to 1.31 4.89 0.03
6MWT distance 
per 10 m
0.96 0.92 to 1.01 2.71 0.06 0.97 0.95 to 1.00 2.98 0.06 – – – –
6MWT distance 
) 468 vs > 468 m
2.40 1.59 to 3.62 17.22 < 0.001 – – – – 2.18 1.18 to 4.03 6.22 0.01
r2 of the model 57.95 < 0.001 61.53 < 0.001
NYHA = New York Heart Association, LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal pro-I type natriuretic peptide, hsCRP = high-sensitivity C-reactive protein, eGFR = 
estimated glomerular ﬁltration rate. HR was analysed for increasing the level of a given variable by r number of units presented in the Table. a6MWT distance as a continuous variable. b6MWT 
distance as a dichotomous variable
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5BCMF. Predictors of 3-year cardiovascular death or hospitalisation in men with chronic heart failure with uni-and multivariate Cox proportional hazard models.
Predictor Univariate model Multivariate modela Multivariate modelb
Hazard 
ratio
95% CI r2 p Hazard 
ratio
95% CI r2 p Hazard 
ratio
95% CI r2 p
Age 
per 10 yr
0.99 0.83 to 1.19 0.01 0.94 0.99 0.97 to 1.01 0.88 0.35 0.99 0.97 to 1.01 0.83 0.36
Ischaemic aetiology 
yes vs no
1.02 0.73 to 1.43 0.01 0.89 1.76 0.95 to 3.28 3.19 0.08 1.81 0.98 to 3.36 3.54 0.07
NYHA class 
(I–II vs III–IV)
1.86 1.47 to 2.34 26.80 < 0.001 1.33 0.92 to 1.95 2.29 0.13 1.49 1.06 to 2.11 5.24 0.02
LVEF% 
per 1%
0.97 0.95 to 0.98 9.54 0.002 1.00 0.97 to 1.03 0.12 0.72 1.00 0.98 to 1.02 0.05 0.82
Diabetes mellitus 
yes vs no
1.09 0.76 to 1.54 0.21 0.65 0.94 0.61 to 1.43 0.09 0.76 0.92 0.60 to 1.41 0.13 0.71
Hypertension 
yes vs no
0.74 0.50 to 1.09 2.36 0.12 0.69 0.33 to 1.44 0.96 0.32 0.67 0.32 to 1.42 1.05 0.31
NT-proBNP 
QFSMPHQHN-
1.41 1.24 to 1.60 28.03 < 0.001 1.22 1.15 to 1.29 9.97 0.002 1.24 1.13 to 1.45 11.62 < 0.001
hsCRP 
QFSMPHNH-
1.56 1.24 to 1.97 14.70 < 0.001 1.05 1.01 to 1.08 3.28 0.01 1.22 0.92 to 1.61 1.97 0.16
Haemoglobin 
QFSHE-
0.86 0.78 to 0.94 9.29 0.002 0.96 0.84 to 1.1 0.11 0.55 0.99 0.87 to 1.12 0.02 0.90
eGFR 
QFSN-NJO2
0.94 0.91 to 0.98 7.27 0.007 0.98 0.92 to 1.03 0.98 0.42 0.99 0.93 to 1.05 0.09 0.76
Uric acid 
QFSNH-
1.22 1.12 to 1.32 22.43 < 0.001 1.12 1.00 to 1.25 4.13 0.04 1.15 1.03 to 1.28 5.95 0.01
6MWT distance 
per 10 m
0.96 0.94 to 0.97 33.54 < 0.001 0.96 0.95 to 0.99 7.82 0.006 – – – –
6MWT distance 
) 468 vs > 468 m
2.16 1.56 to 3.00 21.31 < 0.001 – – – – 1.71 1.08 to 2.72 5.25 0.02
r2 of the model 76.38 < 0.001 75.51 < 0.001
NYHA = New York Heart Association, LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal pro-I type natriuretic peptide, hsCRP = high-sensitivity C-reactive protein, eGFR = 
estimated glomerular ﬁltration rate. HR was analysed for increasing the level of a given variable by r number of units presented in the Table. a6MWT distance as a continuous variable. b6MWT 
distance as a dichotomous variable
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predictors: age, NYHA class, LVEF, diabetes mellitus, 
hypertension, NT-proBNP, hs-CRP, haemoglobin, eGFR, 
uric acid, and distance covered in the 6-minute walk 
test. (The 6-minute walk test distance was included as a 
continuous variable, analysing the effect of a 10 m increase, 
and dichotomously, as ) 468 m vs > 468 m.) Only high level 
of uric acid, a low 6-minute walk test distance, and high 
plasma NT-proBNP remained as signiﬁcant predictors of an 
increase in the composite outcome of 1-year cardiovascular 
death or hospitalisation, as presented in Table 4.
In the 3-year analysis, only a low 6-minute walk test 
distance, high plasma NT-proBNP and a high uric acid 
remained independent predictors of the 3-year risk of death 
and death or hospitalisation. Other parameters did not have 
a signiﬁcant impact on the prediction of death and death or 
hospitalisation, as presented in Table 5 and 6.
For the survival analyses, the distance covered in the 
6-minute walk test was again dichotomised at the median 
value, which was 468 m. The Kaplan-Meier curve showed 
a signiﬁcantly lower survival probability for participants 
who walked ) 468 m, as presented in Figure 1. Similarly, 
the number of participants who survived and remained 
hospitalisation-free was signiﬁcantly lower among those 
who walked ) 468 m, as presented in Figure 2.
Discussion
Three of our study ﬁndings seem to be of particular 
importance. We have shown that a short distance covered 
during the 6-minute walk test is an ominous sign in men 
with heart failure. The distance covered was shown to be 
associated with the stage of heart failure, and proved its 
prognostic value during both the 1-year and the 3-year 
analyses. Moreover, we observed that a shorter distance 
in the 6-minute walk test associated with high plasma 
NT-proBNP and uric acid increased the risk of death or 
hospitalisation for cardiovascular reasons even more during 
the 1- and 3-year follow-up.
Formal cardiopulmonary exercise testing is used as a 
direct indicator of physical capacity during the functional 
examination of heart failure patients (Sarullo et al 2010, 
Poggio et al 2010, Corra et al 2012). However, this expensive 
specialist test is not available at many centres. Moreover, 
the functional status of a patient frequently precludes 
the performance of this test due to the required speed of 
movement. In such cases, exercise tolerance is analysed 
indirectly using a 6-minute walk test. The results of the 
6-minute walk test correlated signiﬁcantly with those of 
cardiopulmonary exercise testing. Thus, the 6-minute walk 
test constitutes a suitable alternative for cardiopulmonary 
exercise testing, with the added beneﬁts of being simple, 
well-tolerated, widely used, and possible to perform under 
any conditions (Zugck et al 2000, Carvalho et al 2011, 
Krevio et al 2004).
Our ﬁnding that a shorter 6-minute walk distance 
corresponded to the clinical stage of heart failure is 
consistent with those of other authors. A shorter distance 
covered in a 6-minute walk test has been documented in 
other individuals with higher NYHA class (Opasich et al 
2001, Shah et al 2001), as well as in older people (Faggiano 
et al 2004), and people with renal dysfunction (Alahdab et 
al 2009).
The 6-minute walk test distance can be used for stratiﬁcation 
of cardiovascular mortality risk. Depending on the clinical 
characteristics of the heart failure patients examined, 
various cut-off values of the 6-minute walk test distance 
have proved their prognostic value (Cahalin et al 1996, 
Bettencourt et al 2000, Rubim et al 2006, Alahdab et al 
2009). In two studies, a walking distance < 200–220 m was 
a cut-off point associated with an increased mortality risk in 
patients with advanced heart failure, NYHA Class III and 
IV (Shah et al 2001, Alahdab et al 2009), while in individuals 
with mild heart failure (NYHA Class II), a distance shorter 
than 520 m increased the 18-month cardiovascular mortality 
risk signiﬁcantly (Rubim et al 2006). Since the 6-minute 
walk test has been used to examine the physical capacity 
of heart failure patients for nearly 30 years, the prognostic 
value of the test could have been modulated by the changing 
standards of pharmacotherapy and invasive treatment, 
irrespective of the clinical characteristics of participants. 
However, because the test remains prognostic, it should be 
Wegrzynowska-Teodorczyk et al: 6-min walk distance in systolic heart failure
Figure 1. Kaplan Meier curve of 3-year survival rates in 
patients stratiﬁed by 6-minute walk test distance ) 468 m 
vs > 468 m.
Figure 2. Kaplan Meier curve reﬂecting 3-year 
hospitalisation-free survival rates in patients stratiﬁed by 
6-minute walk test distance ) 468 m vs > 468 m.
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a component of the complex evaluation of the heart failure 
patient, allowing the establishment of a prognosis.
Most studies analysing the usefulness of the 6-minute 
walk test for stratiﬁcation of mortality risk included 
participants with stable systolic heart failure. However, 
those experiments differed in terms of follow-up duration, 
size of examined groups, and the participants’ age and 
clinical characteristics (Cahalin et al 1996, Rubim et al 
2006, Bettencourt et al 2000, Boxer et al 2010, Reibis et al 
2010, Castel et al 2009). Furthermore, the prognostic value 
of the 6-minute walk test was also conﬁrmed in patients 
with dilated cardiomyopathy (Zugck et al 2000) as well 
as in African American patients hospitalised due to acute 
decompensated heart failure (Alahdab et al 2009).
Our study is unusual because the prognostic value of the 
6-minute walk test was analysed over three years. In most 
previous studies, the prognostic value of the 6-minute walk 
test was analysed over one year (Cahalin et al 1996, Opasich 
et al 2001), 18 months (Zugck et al 2000, Bettencourt et al 
2000, Rubim et al 2006), or two years (Reibis et al 2010, 
Castel et al 2009).
Boxer et al (2010) observed that increasing the walking 
distance by 30 m reduces the mortality risk of heart failure 
patients irrespective of their age, NYHA class, and hsCRP 
level. One should note, however, that this analysis included 
a small number of participants: only 60 participants were 
examined, of whom 20 were excluded from the analysis due 
to other chronic conditions or loss to follow-up. Nevertheless, 
the ﬁndings of that study were conﬁrmed by other authors 
who observed that a greater distance in a 6-minute walk test 
is associated with reduced cardiovascular mortality and this 
effect occurs irrespective of the person’s age (Alahdab et al 
2009, Rubim et al 2006), NYHA class (Boxer et al 2010, 
Reibis et al 2010), LVEF (Zugck et al 2000, Rubim et al 
2006, Castel et al 2009), or hsCRP (Boxer et al 2010).
Another important ﬁnding of our study is that the 6-minute 
walk test remained predictive when hospitalisation for 
cardiovascular reasons was incorporated with death into a 
composite outcome. A relationship between the 6-minute 
walk test distance and hospitalisation has only been reported 
in single studies involving clinically and anthropometrically 
diverse groups of heart failure patients. One such study 
was conducted by Shah et al (2001), who observed that 
increasing the 6-minute walk test distance by 100 m 
decreases the risk of mortality or hospitalisation. However, 
this observation was valid for only one year and solely 
in patients with advanced congestive heart failure. Also, 
Alahdab et al (2009) observed that a distance shorter than 
200 m is associated with higher risk of re-hospitalisation 
and correlates with the number of re-hospitalisations within 
an 18-month period in male African-American patients 
hospitalised due to acute decompensated heart failure. 
However, they did not conﬁrm those relationships with 
regards to female heart failure patients.
The prognosis of heart failure patients is modulated by 
an array of demographic, functional, haemodynamic, and 
neurohormonal factors, including NT-proBNP, hsCRP, and 
uric acid (Cahalin et al 1996, Zugck et al 2000, Rubim et al 
2006, Bettencourt et al 2000, Castel et al 2009, Reibis et al 
2010). Unfortunately, they have not been considered in some 
studies dealing with the relationship between 6-minute 
walk test distance and prognosis in heart failure patients. 
Among these, it was the concentration of NT-proBNP that, 
independently of other clinical parameters, was strongly 
prognostic of mortality and mortality or hospitalisation 
during the 1- and 3-year analyses in our study. This ﬁnding 
is consistent with previously published reports (Park et al 
2010, MacGowan et al 2010).
Our analysis of the mortality and hospitalisation risk factors 
also included other laboratory parameters that play a vital 
role in the diagnosis and treatment of heart failure, such 
as haemoglobin concentration, uric acid, and renal function 
assessed using eGFR. These variables were not taken 
into account in previous studies. Recently, an increasing 
number of authors highlight the important role of uric acid 
as a strong independent prognostic factor in people with 
heart failure. In our study, aside from 6-minute walk test 
and NT-proBNP, uric acid concentration also proved to be 
an independent risk factor of mortality and mortality or 
hospitalisation for cardiovascular reasons. Uric acid levels 
> 7 mg/dL are associated with higher all-cause mortality in 
patients with both acute and chronic heart failure. Thus, it 
is recommended to consider uric acid concentration as an 
additional prognostic marker in heart failure patients, aside 
from previously established clinical prognostic factors 
(Manzano et al 2011, Tamariz et al 2011). Q
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